Company / SG&A Expense
Moleculin Biotech, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$8.8M
FY2025
5-year range
$6.8M / $11.5M
FY2021-FY2025
Trend
-12.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $12M to $9M over the past 2 years.
Based on SEC 10-K filings.
$9M in FY2025 with a 5-year CAGR of +6.8%.
Improved from $12M to $9M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +1.6%
- 5-Year CAGR
- +6.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +6.8%, indicating consistent growth.
- In FY2025, sg&a expense decreased 12.3% year-over-year.
- Peak sg&a expense was recorded in FY2023.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -3.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.8M | -12.3% |
| FY2024 | $10.0M | -13.2% |
| FY2023 | $11.5M | +37.6% |
| FY2022 | $8.4M | +23.6% |
| FY2021 | $6.8M | +7.5% |
| FY2020 | $6.3M | +20.7% |
| FY2019 | $5.2M | +27.8% |
| FY2018 | $4.1M | +71.8% |
| FY2017 | $2.4M | +398.3% |
| FY2016 | $477.8K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026